Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq
Related Experiment Video
Updated: Nov 17, 2025
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Lilibeth Lanceta1, Nadiia Lypova1, Conor O'Neill2
1Department of Medicine, School of Medicine, University of Louisville, Louisville, KY, 40202, USA.
Purpose:
The management of triple-negative breast cancer (TNBC) remains a significant clinical challenge due to the lack of effective targeted therapies. Inhibitors of the cyclin-dependent kinases 4 and 6 (CDK4/6) are emerging as promising therapeutic agents against TNBC; however, cells can rapidly acquire resistance through multiple mechanisms that are yet to be identified. Therefore, determining the mechanisms underlying resistance to CDK4/6 inhibition is crucial to develop combination therapies that can extend the efficacy of the CDK4/6 inhibitors or delay resistance. This study aims to identify differentially expressed genes (DEG) associated with acquired resistance to palbociclib in ER- breast cancer cells.
Methods:
We performed next-generation transcriptomic sequencing (RNA-seq) and pathway analysis in ER- MDA-MB-231 palbociclib-sensitive (231/pS) and palbociclib-resistant (231/pR) cells.
Results:
We identified 2247 up-regulated and 1427 down-regulated transcripts in 231/pR compared to 231/pS cells. DEGs were subjected to functional analysis using Gene Ontology (GO) and the KEGG database which identified many transduction pathways associated with breast cancer, including the PI3K/AKT, PTEN and mTOR pathways. Additionally, Ingenuity Pathway Analysis (IPA) revealed that resistance to palbociclib is closely associated with altered cholesterol and fatty acid biosynthesis suggesting that resistance to palbociclib may be dependent on lipid metabolic reprograming.
Conclusion:
This study provides evidence that lipid metabolism is altered in TNBC with acquired resistance to palbociclib. Further studies are needed to determine if the observed lipid metabolic rewiring can be exploited to overcome therapy resistance in TNBC.
Insights
Triple-negative breast cancer (TNBC) cells develop resistance to palbociclib, a cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor. This resistance is linked to significant alterations in lipid metabolism, particularly cholesterol and fatty acid biosynthesis.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Triple-negative breast cancer (TNBC) lacks targeted therapies, posing a clinical challenge.
- Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors show promise for TNBC, but acquired resistance limits efficacy.
- Understanding resistance mechanisms is vital for developing effective combination therapies.
Purpose of the Study:
- Identify differentially expressed genes (DEGs) associated with acquired resistance to palbociclib in estrogen receptor-negative (ER-) breast cancer cells.
- Investigate the molecular pathways involved in palbociclib resistance.
- Explore the role of lipid metabolism in acquired resistance to CDK4/6 inhibition.
Main Methods:
- Utilized next-generation transcriptomic sequencing (RNA-seq) to compare palbociclib-sensitive and resistant ER- MDA-MB-231 breast cancer cell lines.
- Performed differential gene expression analysis to identify significant transcriptomic changes.
- Conducted pathway analysis using Gene Ontology (GO), KEGG, and Ingenuity Pathway Analysis (IPA) databases.
Main Results:
- Identified 2247 up-regulated and 1427 down-regulated transcripts in resistant cells compared to sensitive cells.
- Pathway analysis revealed significant alterations in PI3K/AKT, PTEN, and mTOR signaling pathways.
- Ingenuity Pathway Analysis (IPA) indicated a strong association between palbociclib resistance and altered cholesterol and fatty acid biosynthesis, suggesting lipid metabolic reprogramming.
Conclusions:
- Acquired resistance to palbociclib in TNBC is associated with significant alterations in lipid metabolism.
- Lipid metabolic rewiring may be a key mechanism driving resistance to CDK4/6 inhibitors in TNBC.
- Further research is warranted to explore targeting lipid metabolism for overcoming therapy resistance in TNBC.
Related Concept Videos
03:21RNA-seq
Before the discovery of RNA-seq, microarray-based methods and Sanger sequencing were used for transcriptome analysis. However, while...
02:24Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...